natgillin/translations-raw huggingface dataset:
Overdosage with oxybutynin has been associated with anticholinergic effects including CNS excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, and urinary retention.
Preveliko odmerjanje oksibutinina lahko vodi do antikolinergi nega u inka vklju no z razdraženostjo centralnega živ nega sistema, vro inskih valov, zvišane telesne temperature, dehidracije, sr ne aritmije, bruhanja in zastajanja urina.
Ingestion of 100 mg oral oxybutynin chloride in association with alcohol has been reported in a 13 year old boy who experienced memory loss, and in a 34 year old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine.
Peroralno jemanje 100 mg oksibutinin klorida v povezavi z alkoholom pri 13- letnem fantu je pokazalo izgubo spomina, pri 34- letni ženski pa se je pojavil stupor, ki mu je sledila motnja orientacije in vznemirjenost, ko se je zbudila, razširjene zenice, sr na aritmija in zastoj urina.
No cases of overdose have been reported with Kentera.
Primeri s prevelikim odmerjanjem Kentera niso znani.
Pharmacotherapeutic group: urinary antispasmodic, ATC code:
Farmakoterapevtska skupina: urospazmolitik, ATC klasifikacija:
Mechanism of action: oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.
Mehanizem delovanja: oksibutinin deluje kot kompetitivni antagonist acetilholina na postganglijske muskarinske receptorje, ki povzro ijo sprostitev gladkih mišic mehurja.
Pharmacodynamic effects:
Farmakodinami ni u inek:
In patients with overactive bladder, characterised by detrusor muscle instability or hyperreflexia, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.
Pri bolnikih z bolj aktivnim mehurjem, za katere je zna ilna nestabilnost detruzorske mišice ali povišano refleksivnostjo, so cistometri ne študije pokazale, da oksibutinin poviša najve jo kapaciteto urinskega mehurja in volumen pove a do prvega skr enja detruzorja.
Oxybutynin thus decreases urinary urgency and the frequency of both incontinence episodes and voluntary urination.
Oksibutinin zato zmanjša potrebo po uriniranju ter s tem pogostost inkontinen nih epizod ter hotnega uriniranja.
Oxybutynin is a racemic (50:50) mixture of R- and S-isomers.
Oksibutinin je racemna (50: 50) zmes R - in S- izomerov.
Antimuscarinic activity resides predominantly in the R-isomer.
Antimuskarinsko delovanje je predvsem prisotno v R- izomeru.
The R-isomer of oxybutynin shows greater selectivity for the M1 and M3 muscarinic subtypes (predominant in bladder detrusor muscle and parotid gland) compared to the M2 subtype (predominant in cardiac tissue).
Oksibutininov R- izomer izkazuje ve jo selektivnost za podtipe muskarina M1 in M3 (prevladujejo v mišici detruzorja mehurja in obušesni žlezi) v primerjavi s podtipom M2 (prevladuje v sr nem tkivu).
The active metabolite, N-desethyloxybutynin, has pharmacological activity on the human detrusor muscle that is similar to that of oxybutynin in vitro studies, but has a greater binding affinity for parotid tissue than oxybutynin.
Aktiven metabolit, N- dezetiloksibutinin, farmakološko vpliva na mišico detruzorja pri loveku, kar je podobno kot u inek oksibutinina pri študijah in vitro, vendar pa je njegova afiniteta za obušesno tkivo ve ja kot pri oksibutininu.
Clinical efficacy:
Klini na u inkovitost:
A total of 957 patients with urge urinary incontinence were evaluated in three controlled studies comparing Kentera to either placebo, oral oxybutynin and/ or tolterodine long acting capsules.
V treh kontroliranih študijah je sodelovalo skupaj 957 bolnikov z urgentno urinarno inkontinenco v primerjavi zdravila Kentera s placebom, peroralnim oksibutininom in/ ali kapsulami tolterodina s podaljšanim sproš anjem.
Reductions in weekly incontinence episodes, urinary frequency, and urinary void volume were evaluated.
Ocenjeno je bilo zmanjšanje tedenskih inkontinen nih epizod, pogostost uriniranja ter volumen izpraznjenega urina.
Kentera led to consistent improvements in overactive bladder symptoms compared with placebo.
Uporaba Kentera je konsekventno izboljšala simptome hiperaktivnega mehurja v primerjavi s placebom.
5 5.2 Pharmacokinetic Properties
5 5. 2 Farmakokineti ne lastnosti
Absorption Kentera has a concentration of oxybutynin sufficient to maintain continuous transport over the 3 to 4 day dosing interval.
Absorpcija Koncentracija oksibutinina v obližu Kentera je zadostna za vzdrževanje stalnega prenosa u inkovine med 3 - do 4- dnevnimi intervali uporabe.
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4ng/ ml.
Po nanosu obliža Kentera naraste koncentracija oksibutinina v plazmi za približno 24 do 48 ur in doseže povpre no maksimalno koncentracijo od 3 do 4ng/ ml.
Steady-state conditions are reached during the second application of the transdermal patch.
Stanje dinami nega ravnovesja je doseženo pri drugi aplikaciji transdermalnega obliža.
The difference in AUC and Cmax of oxybutynin and the active metabolite N-desethyloxybutynin following transdermal administration of Kentera on either the abdomen, buttocks or hip is not clinically relevant.
Razlika med AUC in Cmax oksibutinina in aktivnega metabolita N- dezetiloksibutinina po nanosu transdermalnega obliža Kentera na trebuh, zadnjico ali boke ni klini no relevantna
Distribution Oxybutynin is widely distributed in body tissues following systemic absorption.
Porazdelitev Oksibutinin se po absorpciji preko krvnega obtoka na široko porazdeli v tkivu telesa.
Metabolism Oxybutynin administered orally is metabolised primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall.
Presnova Peroralno zaužit oksibutunin v glavnem presnavljajo citokromski encimski sistemi P450, še posebej CYP3A4, ki ga najdemo v glavnem v jetrih in steni drobovja.
Metabolites include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and N-desethyloxybutynin, which is pharmacologically active.
Med metaboliti sta tudi fenilcikloheksilglikolna kislina, ki je farmakološko neaktivna, in N- dezetiloksibutinin, ki je farmakološko aktiven.
Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyl metabolite.
Transdermalna aplikacija oksibutinina se presnavlja v zgornjem gastrointestinalnem traktu in jetrih ter zmanjšuje nastajanje metabolita N- dezetil.
Excretion Oxybutynin is extensively metabolised by the liver, see above with less than 0.1% of the administered dose excreted unchanged in the urine.
Izlo anje Oksibutinin v veliki meri presnovijo jetra, manj kot 0, 1% odmerka se je izlo ilo z urinom v nespremenjeni obliki.
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Manj kot 0, 1% odmerka se izlo i kot metabolit N- dezetiloksibutinin.
5.3 Preclinical Safety Data
5. 3 Predklini ni podatki o varnosti
Pre-clinical data reveal no special hazard for humans based on studies for acute toxicology, repeat dose toxicity, genotoxicity, carcinogenic potential and local toxicity.
Predklini ni podatki na osnovi študij akutne toksi nosti, toksi nosti pri ponavljajo ih odmerkih, genotoksi nosti, kancerogenega potenciala in lokalne toksi nosti niso razkrili posebnega tveganja za loveka.
At a concentration of 0.4 mg/ kg/ day oxybutynin administered subcutaneously, the occurrence of organ anomalies is significantly increased, but is observed only in the presence of maternal toxicity.
Pri koncentraciji 0, 4 mg/ kg/ dan subkutano danega oksibutinina se je pojavilo pomembno povišanje organskih anomalij, vendar samo v prisotnosti materinske toksi nosti.
Kentera delivers approximately 0.08 mg/ kg/ day.
Kentera vsebuje približno 0, 08 mg/ kg/ dan.
However, in the absence of understanding the association between maternal toxicity and developmental effect, the relevance to human safety cannot be addressed.
Vendar pa zaradi pomanjkanja razumevanja povezanosti med materinsko toksi nostjo in u inkom na razvoj ne moremo dati podatkov za varnost pri loveku.
In the subcutaneous fertility study in rats, while no effects were reported in males, in females, fertility was impaired and a NOAEL (no observed adverse effect level) of 5 mg/ kg was identified.
V raziskavah subkutane plodnosti na podganah ni bilo u inkov na samce, medtem ko so pri samicah opažali zmanjšano plodnost in dolo ili stopnjo NOAEL (stopnja, pri kateri ni opaženih neželenih u inkov) 5 mg/ kg.
6.1 List of Excipients
6. 1 Seznam pomožnih snovi
The transdermal patch is composed of three layers: a backing film, an adhesive/ drug layer and a release liner.
Transdermalni obliž sestavljajo tri plasti: hrbtna plast, plast z lepilom/ zdravilom in folija za nanos.
The backing film provides the matrix system with occlusivity and physical integrity and protects the adhesive/ drug layer.
Hrbtna plast vsebuje zaprt, fizi no integriran matri ni sistem in š iti plast z lepilom/ zdravilom.
The adhesive/ drug layer contains oxybutynin and triacetin.
Plast z lepilom/ zdravilom vsebuje oksibutinin in triacetín.
The release liner is two overlapped siliconised polyester strips that are peeled off and discarded by the patient prior to applying the patch.
Pred aplikacijo obliža ju bolnik odstrani in zavrže.
Backing Film:
Hrbtna plast:
Polyethylene/ ethyl vinyl acetate (PET/ EVA), clear
Polietilen/ etil vinil acetat (PET/ EVA), prozoren
6 Middle layer:
6 Plast za nanos:
Siliconised Polyester
Silikonizirani poliester
The transdermal patches are individually contained in LDPE/ paper laminate sachets and supplied in Patient Calendar Boxes of 2, 8 or 24 patches.
Transdermalni obliži so posami no pakirani v LDPE/ papirnate vre ke in zloženi v škatlice s koledarji s po 2, 8 ali 24 obližev.
6.6 Instructions for use and handling
6. 6 Navodila za pripravo in ravnanje z zdravilom
Apply immediately upon removal from the protective sachet.
Nanesite takoj po odstranitvi zaš itne vre ke.
After use the patch still contains substantial quantities of active ingredients.
Po uporabi obliž še vedno vsebuje znatne koli ine zdravilne u inkovine, ki škodljivo vplivajo na organizme v vodnem okolju.
Remaining active ingredients of the patch may have harmful effects if reaching the aquatic environment.
Zato uporabljen obliž prepognite na pol z lepljivo stranjo navznoter, tako da prekrijete membrano za sproš anje in ga položite v originalno zaš itno vre ko.
Hence, after removal, the used patch should be folded in half, adhesive side inwards so that the release membrane is not exposed, placed in the original sachet and then discarded safely out of reach of children.
Odstranite varno, izven dosega otrok.
Used patches should not be flushed down the toilet nor placed in liquid waste disposal systems.
Uporabljenih obližev ni dovoljeno splakniti v kanalizacijo ali odstraniti v sistem teko ih odpadkov.
Nicobrand Limited 189 Castleroe Road Coleraine Northern Ireland BT51 3RP
Nicobrand Limited 189 Castleroe Road Coleraine Northern Ireland BT51 3RP
8 ANNEX II
8 A
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
IMETNIK DOVOLJENJA SPROŠ ANJE SERIJE
B.
ZA
CONDITIONS OF THE MARKETING AUTHORISATION
ODGOVOREN
9 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
ZA
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca zdravila, odgovornega za sproš anje serije
Nicobrand Limited 189 Castleroe Road, Coleraine BT51 3RP Northern Ireland
Nicobrand Limited 189 Castleroe Road, Coleraine BT51 3RP Severna Irska
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
Imetnik tega dovoljenja za promet z zdravilom mora obvestiti Evropsko komisijo o na rtu trženja za zdravilo, odobreno s to odlo bo.
LABELLING AND PACKAGE LEAFLET
OZNA EVANJE
LABELLING
11 PODATKI NA ZUNANJI OVOJNINI ALI STI NI OZ.
CARTON (Containing 8 transdermal patches)
ŠKATLICA (vsebuje 8 transdermalnih obližev)
Kentera 3.9 mg / 24 hours transdermal patch Oxybutynin
Kentera 3, 9 mg / 24 h transdermalni obliž Oxybutynin
STATEMENT OF ACTIVE SUBSTANCE(S)
NAVEDBA ENE ALI VE ZDRAVILNIH U INKOVIN
Each patch contains 36 mg oxybutynin.
Vsak obliž vsebuje 36 mg oksibutinina.
The area of the patch is 39 cm2 releasing a nominal 3.9 mg of oxybutynin per 24 hours.
Površina obliža 39 cm2 sproš a nominalnih 3, 9 mg oksibutinina na 24 ur.
Triacetin; acrylic adhesive (containing 2-ethylhexyl acrylate; N-vinyl pyrrolidone and hexamethyleneglycol dimethacrylate polymer domains).
Pomožne snovi: triacetín; akrilno lepilo (vsebuje podro ja 2- etilheksil akrilat N- vinil pirolidona in heksametileneglikol dimetakrilatnega polimera).
Backing: polyester/ ethylene-vinyl acetate film; siliconised polyester film.
Hrbtna plast: poliester/ plast iz etilen- vinil acetata; silikonizirana poliesterska plast.
Do not use if seal on sachet is broken
Ne uporabljajte, e je zavoj odprt.
Apply immediately upon removal from sachet.
Nanesite takoj po odstranitvi zaš itne vre ke.
Read the package leaflet before use.
Pred uporabo natan no preberite navodilo.
Date :< MM/YYYY >
Uporabno do: < MM/ LLLL >
MARKETING AUTHORISATION NUMBER (S)
ŠTEVILKA( E) DOVOLJENJA ZA PROMET
MANUFACTURER’ S BATCH NUMBER
IZDELOVAL EVA ŠTEVILKA SERIJE IZDELAVE ZDRAVILA
Batch No. :< >
Serija: < >
Sun/ Wed Mon/ Thu Tue/ Fri Wed/ Sat Thu/ Sun Fri/ Mon Sat/ Tue
Ned/ Sre Pon / et Tor/ Pet Sre/ Sob et/ Ned Pet/ Pon Sob/ Tor
14 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
13 PODATKI, KI MORAJO BITI NAVEDENI NA ZUNANJEM OVITKU ALI NOTRANJEM TRAKU, E ZUNANJEGA OVITKA NI
CARTON (Containing 24 transdermal patches)
ŠKATLICA (Vsebuje 24 transdermalnih obližev)
Kentera 3.9 mg / 24 hours transdermal patch Oxybutynin
Kentera 3. 9 mg / 24 h transdermalni obliž Oxybutynin
The area of the patch is 39 cm2 releasing a nominal 3.9 mg of oxybutynin per 24 hours.
Površina obliža 39 cm2 sproš a nominalnih 3. 9 mg oksibutinina na 24 ur.
Triacetin; acrylic adhesive (containing 2-ethylhexyl acrylate, N-vinyl pyrrolidone and hexamethyleneglycol dimethacrylate polymer domains).
Pomožne snovi: triacetín; akrilno lepilo (vsebuje podro ja 2- etilheksil akrilat N- vinil pirolidona in heksametileneglikol dimetakrilatnega polimera).
For transdermal use only Do not use if seal on sachet is broken.
Ne uporabljajte, e je zavoj odprt
Read package leaflet before use.
Pred uporabo natan no preberite navodila.
Keep out of the reach and sight of children.
Zdravilo hranite izven dosega in pogleda otrok.
Date :< MM/YYYY >
Uporabno do: < MM/ YYYY >
Store in original package.
14 Hranite v originalnem ovitku.
Do not freeze.
Ne hranite v hladilniku ali zamrzujte.
MANUFACTURER’ S BATCH NUMBER
SERIJSKA ŠTEVILKA IZDELAVE ZDRAVILA
Batch No. :< >
Serija št.: < >
16 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
16 PODATKI, KI MORAJO BITI NAVEDENI NA ZUNANJEM OVITKU ALI NOTRANJEM TRAKU, E ZUNANJEGA OVITKA NI
CARTON (Containing 2 transdermal patches)
ŠKATLICA (Vsebuje 2 transdermalnih obližev)
Store in original package.
Hranite v originalnem ovitku.
18 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
18 PODATKI, KI MORAJO BITI NAVEDENI VSAJ NA MANJŠIH STI NIH OVOJNINAH
SACHET (Contains 1 transdermal patch)
VRE KA (vsebuje 1 transdermalni obliž)
Kentera 3.9 mg / 24 hours transdermal patch Oxybutynin
Oxybutynin
For transdermal use only
Samo za transdermalno uporabo.
Apply immediately upon removal from sachet.
Nanesite takoj, ko odstranite vre ko.
Read all of this leaflet carefully before you start using Kentera
Pred uporabo obliža Kentera natan no preberite priloženo navodilo!
- If you have further questions, please ask your doctor or your pharmacist.
- e imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
It may
Drugim osebam bi lahko
harm them even if their symptoms are the same as yours.
celo škodovalo, eprav imajo znake bolezni, podobne vašim.
1. What Kentera is and what it is used for 2. Before you use Kentera 3. How to use Kentera 4. Possible side effects 5. Storing Kentera 6.
Shranjevanje zdravilaKentera 6.
Kentera 3.9 mg / 24 h transdermal patch
Kentera 3, 9 mg / 24 h transdermalni obliž
The active substance is oxybutynin.
Zdravilna u inkovina je oksibutinin.
The other ingredients are triacetin, acrylic adhesive solution (containing 2-ethylhexyl acrylate, N- vinyl pyrrolidone and hexamethyleneglycol dimethacrylate polymer domains), clear backing film of polyester/ ethylene vinyl acetate (PET/ EVA), and siliconised polyester release liner (PET).
Druge sestavine so triacetín, akrilna lepljiva raztopina (vsebuje podro ja 2- etilheksil akrilat, N- vinil pirolidona in heksametileneglikol dimetakrilatnega polimera), prosojna hrbtna plast iz poliestra/ etilen vinil acetata (PET/ EVA) in silikonizirane poliesterske folije za nanos (PET).
Kentera is a thin, flexible, translucent transdermal patch that you apply to your skin.
Kentera je tanek, prilagodljiv, prosojen transdermalni obliž, ki ga nanesete na kožo.
Oxybutynin, the active substance in the patch, is dissolved in the thin layer of adhesive, which is used to stick the patch to your skin.
Zdravilna u inkovina oksibutinin v obližu je raztopljena v tanki plasti lepila s katerim obliž nalepite na kožo.
Each pack contains either 2, 8 or 24 patches.
Vsako pakiranje vsebuje 2, 8 ali 24 obližev.
Kentera controls the symptoms of urge incontinence and/ or increased urinary frequency and urgency.
Kentera nadzoruje simptome urgentne inkontinence in/ ali povišane pogostosti uriniranja ter urgentnosti.
BEFORE YOU USE KENTERA
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO KENTERA
Do not use Kentera:
Ne uporabljajte zdravila Kentera:
If you have allergies to medical tape or other transdermal patches, consult your doctor before using Kentera.
e ste preob utljivi na (alergi ni za) oksibutinin ali druge sestavine zdravila Kentera. e ste alergi ni na lepilo zdravila ali druge transdermalne obliže, se pred uporabo zdravila Kentera posvetujte z zdravnikom.
If you experience incomplete bladder emptying during urination, the use of oxybutynin may increase this problem.
e imate težave z nepopolnim praznjenjem mehurja med uriniranjem, lahko uporaba oksibutinina težavo še pove a.
21 If you have digestion problems caused by reduced emptying of the stomach after a meal you should consult your doctor before using Kentera.
21 e imate prebavne težave, ki jih povzro a zmanjšano praznjenje želodca po obroku, se pred uporabo Kentera posvetujte z zdravnikom.
If you have glaucoma or a family history of glaucoma, tell your doctor.
Zdravniku povejte, e imate glavkom ali družinsko anamnezo glavkoma.
If you have any of the following: • Liver disease • Kidney disease • Bladder obstruction • Gastrointestinal obstruction • Ulcerative colitis • Generalized muscle weakness • Inflammation of the oesophagus
• Jetrno obolenje • Ledvi no obolenje • Obstrukcijo mehurja • Gastrointestinalno obstrukcijo • Ulcerozni kolitis
Since treatment with oxybutynin may cause decreased perspiration, there is an increased risk of fever and heat stroke if you are exposed to high environmental temperatures.
Zdravljenje z oksibutininom lahko povzro i zmanjšano znojenje, zato pride ob izpostavljenosti visokim okoljskim temperaturam do povišanega tveganja vro ine in vro inske kapi.
Kentera is not recommended for use in children or adolescents.
Obliža Kentera ne priporo amo za uporabo pri otrocih in mladostnikih.
Kentera with food and drink:
Uporaba obližev Kentera skupaj s hrano in pija o:
Oxybutynin may cause drowsiness or blurred vision.
Oxybutynin lahko povzro i zaspanost in zamegljen vid.
Drowsiness may be increased by consumption of alcohol.
Uživanje alkohola lahko zaspanost še pove a.
Pregnancy
Nose nost
Kentera should not to be used during pregnancy unless clearly necessary
Med nose nostjo ne uporabljajte obližev Kentera, razen e je to nujno potrebno.
It is not known whether oxybutynin is excreted in human milk.
Ni znano, ali se oksibutinin izlo a v materino mleko.
Caution should be exercised when using Kentera when you are breast feeding.
Pri uporabi obližev Kentera med dojenjem bodite pazljivi.
Kentera may cause drowsiness or blurred vision, requiring caution when driving or operating machines.
Kentera lahko povzro i omoti nost ali zamegljen vid, zato bodite med vožnjo ali upravljanjem strojev pazljivi.
Please inform your doctor or pharmacist if you are taking or have recently taken other medicinal products whether prescribed or not.
Obvestite svojega zdravnika ali farmacevta, e jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi e ste ga dobili brez recepta.
You should check with your doctor or pharmacist if you are unsure.
Kentera vedno uporabljajte natan no po navodilih zdravnika. e o uporabi niste prepri ani, se posvetujte z zdravnikom ali farmacevtom.
Change the patch on the same two days every week, for example, every Sunday and Wednesday or Monday and Thursday.
Obliž menjajte na vedno enaka dneva v tednu, na primer vsako nedeljo in sredo, ali vsak ponedeljek in etrtek.
Printed on the inside flap of your Kentera package, you will find a Kentera calendar checklist that will help you to remember your dosing schedule.
Na notranji strani škatlice Kentera je natisnjen koledar ek s kontrolnim seznamom za lažji
Mark the schedule you plan to follow and remember always to change your patch on the same two days of the week you have chosen on your calendar.
Ozna ite urnik, po katerem boste zdravilo nanašali in obliž menjajte na vedno enaka dneva v tednu, ki ste ju izbrali na koledarju.
Make sure to wear only one patch at a time and wear your patch continuously, until it is time to apply a new one.
Prepri ajte se, da naenkrat nanesete samo en obliž in da ga nosite nepretrgoma do zamenjave z novim.
Where to Apply
Kje uporabljati obliž
Apply the patch to a clean, dry, smooth area of skin on your abdomen, hips or buttocks.
Obliž nanesite na ist, suh, gladek predel kože na trebuhu, bokih ali zadnjici.
Do not expose the patch the sun.
Ne izpostavljajte obliža soncu.
Place the patch underneath your clothing.
Obliž namestite pod obla ila.
Rotate application sites with each new application.
Vsaki izberite drugo mesto nanosa.
abdomen
trebuh
hips
boki
buttocks
zadnjica
How to Apply
Kako uporabljati obliž
Each patch is individually sealed in a protective sachet.
Vsak obliž je posami no zapakiran v zaš itno vre ko.
Step 1:
Prvi korak:
Choose a spot for the patch that is:
Izberite mesto za namestitev obliža, ki je:
• Freshly washed, but dry and cool (wait a few minutes after taking a hot bath or shower). • Free of body powder, lotion, and oil. • Free of cuts, rashes or any other skin irritation.
• Pravkar umito, vendar suho in hladno (po akajte nekaj minut, e ste se prhali ali kopali v vro i vodi). • Na katerem nimate pudra, kreme ali olja. • Na katerem nimate vreznin, izpuš ajev ali kako druga e razdražene kože.
Step 2:
Drugi korak:
Open the sachet that contains the patch.
Odprite vre ko z obližem.
• Tear open along arrows marked on the right side of the sachet as shown in drawing below. • Do not cut the sachet with scissors, which might damage the patch inside. • Pull the patch out. • Apply immediately to your skin; do not keep or store the patch outside the sealed sachet.
• Vre ko raztrgajte vzdolž puš ic na desni strani, kot je prikazano na sliki spodaj. • Vre ke ne odpirajte s škarjami, ker lahko poškodujete obliž. • Izvlecite obliž. • Nemudoma ga nanesite na kožo; obliža ne shranjujte izven zaprte zaš itne vre ke.
23 Step 3:
Tretji korak:
Apply one half of the patch to your skin.
Na kožo nalepite polovico obliža.